Polymorphisms of UGT1A1*6 UGT1A1*7 & UGT1A1*8 in three major ethnic groups from Malaysia

Indian Journal of Medical Research

Volumn 136, Issue 2, 2012, Pages 249-259

  Teh, L K ^a   Hashim, H ^a   Zakaria, Z A ^a,b   Salleh, M Z ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Genetic polymorphism; Interethnic; Irinotecan; UGT1A1

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; PHARMACOLOGICAL BIOMARKER;

AFRICAN AMERICAN; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CHINESE; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; ENZYME ACTIVITY; ETHNIC GROUP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; INDIAN; MALAYSIA; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRESCRIPTION; PREVALENCE; RANDOMIZATION; VALIDATION PROCESS; BLOOD; GENETICS; METHODOLOGY; PHARMACOGENETICS;

BIOMARKERS, PHARMACOLOGICAL; CAMPTOTHECIN; ETHNIC GROUPS; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALAYSIA; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84867075860     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. U.S. Food and Drug Administration. (2005). Hepatic dysfunction, pancreatitis, UGT1A1. July 21, 2005; Final Label FDA approval drug label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020571s024,027, 028lbl.pdf, accessed on May 22, 2011.
2. U.S. Food and Drug administration. May 2010. Camptosar (irinotecan hydrochloride) injection: FDA approval drug label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020571s031s032s 033s036s037lbl.pdf, accessed on June 12, 2011.
3. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, Lee EJD, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005; 59: 415-424.
4. Ratain MJ. Irinotecan dosing: does the CPT in CPT-1 1 stand for "Can't Predict Toxicity". J Clin Oncol 2002; 20: 7-8.
5. Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939-950.
6. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mamalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15: 677-685.
7. Farheen S, Sengupta S, Santra A, Pal S, Dhali GK, Chakravorty M, et al. Gilbert's syndrome: high frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene. World J Gastroenterol 2006; 12: 2269-2275.
8. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: What is the right star? J Clin Oncol 2006; 24: 2221-2224.
9. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-2244.
10. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
11. Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001; 26: 205-211.
12. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer AD, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDPglucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
13. Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009; 14: 136-142.
14. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421 C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007; 98: 1461-1467.
15. Huang CS, Luo GA, Huang ML, Yu SC, Yang SS. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics 2000; 10: 539-544.
16. Premawardhena A, Fisher CA, Liu YT, Verma IC, de Silva S, Arambepola M, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 2003; 31: 98-101.
17. Akaba K, Kimura T, Sasaki A, Tanabe S, Wakabayashi T, Hiroi M, et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate- glucuronosyltransferase gene in Japanese. J Hum Genet 1999; 44: 22-25.
18. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97: 1255-1259.
19. Kaniwa N, Kurose K, Tinno H, Tanaka-Kagawa T, Saito Y, Saeki M, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686 C>T (P229L) found in an African-American. (2005). Drug Metab Dispos 2005; 33: 458-465.
20. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and*28. Pharmacogenet Genomics 2007; 17: 497-504.
21. Zainuddin Z, Teh LK, Suhaimi AW, Ismail R. Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. J Clin PharmTher 2006; 31: 187-191.
22. Ismail R, Teh L K. Genetic polymorphism of CYP2D6: Malaysian Indians have the highest frequency for CYP2D6*4 in Asia. Eur J Clin Pharmaco 2001; 57: 617-618.
23. National Cancer Registry. Second Report of the Cancer incidence in Malaysia. Kuala Lumpur, Malaysia, National Cancer Registry: Ministry of Health Malaysia; 2004. Available from: http://www.radiologymalaysia.org/Archive/NCR/2ndNCR.pdf, accessed on December 12, 2008.